AI-generated analysis. Always verify with the original filing.
Palisade Bio, Inc. entered into a master services agreement with Iterative Health to support patient enrollment for its upcoming Phase 2 study of PALI-2108 in moderate-to-severe ulcerative colitis and concurrently sold 1,536,885 shares of common stock to an Iterative Health affiliate for $3.0 million in an unregistered offering.
This filing reflects two interrelated strategic actions supporting Palisade Bio’s advancement of PALI-2108 into Phase 2 for ulcerative colitis: a service partnership with Iterative Health to expedite patient enrollment, and a concurrent $3.0 million private placement with an affiliate of that same partner. The master services agreement is operationally focused—designed specifically to accelerate Study Enrollment—indicating the Company is moving toward active clinical execution. The equity financing, priced at the five-day pre-closing Nasdaq average ($1.952/share), is structured as a Section 4(a)(2) exempt transaction, avoiding registration requirements while securing capital from a collaborator with domain expertise in clinical trial operations. Though the amount is modest relative to typical biotech Phase 2 financings, the alignment between service delivery and capital commitment suggests a de-risked, milestone-aware engagement model. No use-of-proceeds disclosure limits assessment of funding sufficiency for the upcoming study, and no forward-looking guidance on timelines, endpoints, or go/no-go criteria is provided beyond reference to the 'expected' Phase 2 study.
Event Type
Disclosure
Voluntary
Variant
8-K
. Other Events.** In preparation for the expected Phase 2 study of PALI-2108 for the treatment of patients with moderate to severe Ulcerative Colitis (“UC”), an
Material Agreement